Gritstone bio, Inc. (GRTS)
After hours:
| Previous Close | 12.01 |
| Open | 11.68 |
| Bid | 12.19 x 800 |
| Ask | 12.26 x 4000 |
| Day's Range | 11.68 - 12.52 |
| 52 Week Range | 2.86 - 35.20 |
| Volume | |
| Avg. Volume | 1,235,804 |
| Market Cap | 830.131M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings Date | Nov. 03, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.67 |
- GlobeNewswire
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines (CORAL program) T cell immunity against conserved non-Spike epitopes may offer clinical benefit Gritstone-sponsored, CEPI-funded Phase 1 study of Spike (Beta variant) plus novel TCE constructs expected to initiate in South Africa by year end Initial Phase 1 data from Gritstone-sponsored UK study expected early in the first quarter o
- GlobeNewswire
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted fourteen employees nonqualified stock options to purchase an aggregate of 109,000 shares of its common stock with an exercise price of $10.87, which is equal to the closing price of Gritstone’s common stock on November 16, 2
- GlobeNewswire
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques Potential for equivalent or more potent immune responses at lower doses with SAM compared to first-generation mRNA vaccines; strong T cell responses observed Initial Phase 1 data from Gritstone-sponsored CORAL study expected early in the first Quarter 2022 EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nas
